Skip to main content

Table 2 Long-term protection of mice surviving the i.p. challenge with viable tumor cells.

From: Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity

Group

Number of micea

Proportion of survivors (%)b

Average survival AM ± SE (days)

p-valuec

Control

27

0.0

18.00 ± 1.14

 

1 × 90d*

8

75.0

83.75 ± 10.96

<0.0001

2 × 90d*

14

85.7

92.86 ± 4.91

<0.0001

3 × 90d*

19

73.7

90.89 ± 4.25

<0.0001

1 × 60d**

6

66.7

73.00 ± 17.08

<0.0001

2 × 60d**

16

87.5

92.50 ± 5.35

<0.0001

3 × 60d**

16

81.3

90.19 ± 5,63

<0.0001

1 × 30d***

7

57.1

79.14 ± 12.10

<0.0001

2 × 30d***

15

80.0

94.20 ± 12.38

<0.0001

3 × 30d***

20

100.0

100.00 ± 0.00

<0.0001

  1. Mice surviving the i.p. challenge with 5 × 105 B16F1 viable tumor cells were re-challenged with the same number of viable tumor cells without additional treatment.
  2. a number of animals which survived 100 days after first tumor challenge
  3. b surviving animals - are animals which survived at least 100 days after tumor challenge
  4. c p-value: group compared to control group
  5. * vaccination started 90 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
  6. ** vaccination started 60 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
  7. *** vaccination started 30 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) in 15 days interval or three times (3×) in 15 days interval, except for the last vaccination, which was performed 7 days after second vaccination
  8. The experiment was repeated three times.